Genetic variations of superoxide dismutase 2 and cytochrome P450 2E1 in non-alcoholic steatohepatitis

Liver International

Volumn 34, Issue 6, 2014, Pages 931-936

  Huang, Yi Shin ^a   Chang, Chih Hao ^a   Lin, Tai Ling ^a   Perng, Chin Lin ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cytochrome P450 2E1; Fatty liver; Genetic variation; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Non alcoholic steatosis; Superoxide dismutase 2

Indexed keywords

CYTOCHROME P450 2E1; MANGANESE SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; LIVER DISEASE; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; NON ALCOHOLIC STEATOSIS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; STEATOSIS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; ENZYMOLOGY; EPIDEMIOLOGY; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PHENOTYPE; RISK FACTOR;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; CYTOCHROME P-450 CYP2E1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE; RISK FACTORS; SUPEROXIDE DISMUTASE;

EID: 84902548277     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12533     Document Type: Article

References (33)

1. Farrell GC, Chitturi S, Lau GKK, Sollano J, The Asia-Pacific working party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007;22: 775-7.
2. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-84.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the amercain gastroenterological association. Hepatology 2012; 55: 2005-23.
4. Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis 2011; 31: 128-46.
5. Dhar SK, St Clair DK. Manganese superoxide dismutase regulation and cancer. Free Radic Biol Med 2012; 52: 2209-22.
6. Crawford A, Fassett RG, Geraghty DP, et al. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene 2012; 501: 89-103.
7. Wang S, Wang F, Shi X, et al. Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk: a meta-analysis. Eur J Cancer 2009; 45: 2874-81.
8. Sutton A, Khoury H, Prip-Buus C, et al. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003; 13: 145-57.
9. Sutton A, Imbert A, Igoudjil A, et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005; 15: 311-9.
10. Degoul F, Sutton A, Mansouri A, et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 2001; 120: 1468-74.
11. Nahon P, Sutton A, Pessayre D, et al. Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death. Clin Gastroenterol Hepatol 2005; 3: 292-8.
12. Sutton A, Nahon P, Pessayre D, et al. Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res 2006; 66: 2844-52.
13. Stewart SF, Leathart JB, Chen Y, et al. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology 2002; 36: 1355-60.
14. Namikawa C, Zhang SP, Vyselaar JR, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004; 40: 853-6.
15. El-Koofy NM, El-Karaksy HM, Mandour IM, et al. Genetic polymorphisms in non-alcoholic fatty liver disease in obese Egyptian children. Saudi J Gastrolenterol 2011; 17: 265-70.
16. Al-serri A, Anstee QM, Valenti L, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 2012; 56: 448-54.
17. Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37: 544-55.
18. Wu CW, Yu J. Molecular basis for a functional role of cytochrome P450 2E1 in non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2010; 25: 1019-20.
19. Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011; 35: 630-7.
20. Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013; 58: 395-8.
21. Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 2005; 569: 101-10.
22. Yu MW, Gladek-Yarborough A, Chiamprasert S, et al. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995; 109: 1266-73.
23. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genetic polymorphism and the susceptibility to anti-tuberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-30.
24. Varela NM, Quinones LA, Orellana M, et al. Study of cytochrome p450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women. Biol Res 2008; 41: 81-92.
25. Piao YF, Li JT, Shi Y. Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. World J Gastroenterol 2003; 9: 2612-5.
26. Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47: 128-34.
27. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005; 280: 9887-94.
28. Kathirvel E, Morgan K, French SW, Morgan TR. Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009; 21: 973-83.
29. Kathirvel E, Chen P, Morgan K, French SW, Morgan TR. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol 2010; 25: 1136-43.
30. Watanabe J, Hayashi S, Kawajiri K. Different regulations and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′ flanking region. J Biochem 1994; 116: 321-6.
31. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphism in the 5′-flanking region change transcriptional regulation of the human cytochrome P-450 II E1 gene. J Biochem 1991; 110: 559-65.
32. Powell H, Kitteringham NR, Pirmohamed M, Smith DA, Park BK. Expression of cytochrome P-4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 1998; 8: 11-21.
33. Lucas D, Ménez C, Girre C, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 1995; 5: 298-304.